We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
176
iShares Russell 2000 ETF
IWM
$82.7B
– –
-2,300
Closed -$566K
LULU icon
177
lululemon athletica
LULU
$13.6B
– –
-2,240
Closed -$465K
META icon
178
Meta Platforms (Facebook)
META
$1.51T
– –
-800
Closed -$528K
MOH icon
179
Molina Healthcare
MOH
$11.1B
– –
-46,626
Closed -$8.09M
MRNA icon
180
Moderna
MRNA
$25.2B
– –
-7,711
Closed -$227K
NEO icon
181
NeoGenomics
NEO
$2.05B
– –
-278,286
Closed -$3.27M
NTLA icon
182
Intellia Therapeutics
NTLA
$1.64B
– –
-2,978
Closed -$26.8K
ORIC icon
183
Oric Pharmaceuticals
ORIC
$1.43B
– –
-9,706
Closed -$79.4K
PLNT icon
184
Planet Fitness
PLNT
$3.83B
– –
-3,173
Closed -$344K
PLTR icon
185
Palantir
PLTR
$423B
– –
-2,500
Closed -$444K
QURE icon
186
uniQure
QURE
$3.28B
– –
-4,763
Closed -$114K
RNAM
187
DELISTED
Avidity Biosciences
RNAM
– –
-2,630,969
Closed -$190M
ROIV icon
188
Roivant Sciences
ROIV
$26.2B
– –
-108,039
Closed -$2.34M
SIBN icon
189
SI-BONE Inc
SIBN
$848M
– –
-90,331
Closed -$1.78M
SNY icon
190
Sanofi
SNY
$105B
– –
-5,851
Closed -$284K
TRVI icon
191
Trevi Therapeutics
TRVI
$2.62B
– –
-7,603
Closed -$95.2K
TYRA icon
192
Tyra Biosciences
TYRA
$1.52B
– –
-3,143
Closed -$82.6K
VKTX icon
193
Viking Therapeutics
VKTX
$3.86B
– –
-68,665
Closed -$2.42M
BTSG icon
194
BrightSpring Health Services
BTSG
$12.2B
– –
-92,095
Closed -$3.45M
MAZE
195
Maze Therapeutics
MAZE
$1.52B
– –
-887,708
Closed -$36.8M
4 5 6 7
8

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.